Adele GLP-1: The Private-Clinic Pathway They Likely Used

What the Timeline Actually Tells Us

Adele's transformation became visible to the public during the summer of 2020 and accelerated through 2021. That window is not random. Semaglutide 2.4 mg (Wegovy) received FDA approval in June 2021, but subcutaneous semaglutide at lower doses had been available to UK and US private weight-management clinics under off-label or compounded protocols since the commercial launch of Ozempic (semaglutide 1.0 mg for type 2 diabetes) in 2018. A private physician could legally prescribe 0.5 mg or 1.0 mg semaglutide for weight management before June 2021 under shared decision-making standards.

The 2020 to 2022 Window Matches Drug Availability

Liraglutide 3.0 mg (Saxenda) was FDA-approved for chronic weight management as early as December 2014 and has been available through UK private clinics since 2017. Any private physician treating Adele in that period had at least two GLP-1 options on the table. The SCALE Obesity trial (N=3,731) showed liraglutide 3.0 mg produced a mean weight loss of 8.4 kg versus 2.8 kg for placebo over 56 weeks [1].

Why the Sirtfood Diet Alone Cannot Explain the Result

Adele's trainer at the time publicly referenced the sirtfood diet, a 1,000-calorie-per-day Phase 1 protocol built around polyphenol-rich foods. That plan produces rapid early weight loss, but independent dietitians have noted it is nutritionally inadequate for sustained results beyond eight weeks. A loss of approximately 45 kg requires a sustained caloric deficit over 18 to 24 months. GLP-1 receptor agonists suppress appetite through hypothalamic pathways and slow gastric emptying, making that kind of sustained deficit physiologically far more manageable [2].

How a UK or US Private Clinic Structures a GLP-1 Protocol

Private clinics offering GLP-1 therapy follow a broadly consistent intake and titration framework. The process is not a single prescription. It is a managed program that typically spans six to eighteen months.

Step 1: Intake Screening and Lab Work

Before any prescription is written, a compliant private clinic orders a baseline panel. This includes fasting glucose, HbA1c, a full lipid panel, thyroid-stimulating hormone (TSH), a comprehensive metabolic panel, and a personal plus family history screen for medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2). Both MTC and MEN2 are absolute contraindications listed in the Wegovy prescribing information [3].

BMI thresholds matter for on-label prescribing. The FDA label for Wegovy requires a BMI of 30 or above, or BMI of 27 or above with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea [3]. Private clinics working off-label may use different thresholds under physician discretion, but the clinical standard does not support prescribing to patients with a healthy BMI.

Step 2: Drug Selection

At the point Adele's transformation appears to have begun, a UK or US private physician would have chosen between two agents with meaningful evidence.

Liraglutide 3.0 mg (Saxenda). Daily subcutaneous injection. Available earlier. The SCALE Obesity and Prediabetes trials established the evidence base. The prescribing information recommends discontinuation if 4% weight loss has not occurred by week 16 [4].

Semaglutide 0.5 to 1.0 mg (Ozempic, off-label for weight). Weekly subcutaneous injection. More convenient dosing. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo (P<0.001) [5]. At doses available before June 2021, clinicians used 0.5 mg and 1.0 mg off-label and observed meaningful weight reduction, though not at the magnitude of the 2.4 mg maintenance dose.

The weekly injection schedule of semaglutide makes adherence substantially easier for someone with a demanding travel and performance schedule. That practical factor likely tips the choice toward semaglutide for most high-functioning private patients.

Step 3: Titration Schedule

Standard semaglutide titration for weight management follows a four-week escalation pattern. The table below reflects the schedule in the Wegovy prescribing information [3].

| Weeks | Weekly Dose | |-------|-------------| | 1 to 4 | 0.25 mg | | 5 to 8 | 0.5 mg | | 9 to 12 | 1.0 mg | | 13 to 16 | 1.7 mg | | 17+ | 2.4 mg (maintenance) |

A private clinic may slow this schedule if a patient experiences significant nausea, vomiting, or diarrhea. The most common reason patients drop out of GLP-1 trials is gastrointestinal side effects, which affected 44% of semaglutide participants in STEP-1 versus 16% of placebo participants [5]. Slowing the titration to eight-week intervals per dose level reduces dropout and is well within prescriber discretion.

Step 4: Adjunct Lifestyle Support

No responsible private clinic prescribes a GLP-1 agonist without dietary and behavioral support. The Endocrine Society's 2015 Obesity Pharmacotherapy Guidelines state that pharmacotherapy should be used "as an adjunct to a comprehensive lifestyle intervention" [6]. A 500 to 750 kcal daily deficit, achieved through diet composition rather than extreme restriction, is the standard recommendation alongside GLP-1 therapy.

A modified sirtfood-style diet, high in polyphenols and moderate in protein, is not incompatible with GLP-1 therapy. The appetite suppression from semaglutide makes adherence to a structured eating plan significantly easier, which may explain why the sirtfood angle was emphasized in press coverage while the pharmacological support remained unconfirmed.

Monitoring During GLP-1 Therapy: What Responsible Clinics Do

A six-month private GLP-1 program at a quality clinic does not end at the prescription pad. Ongoing monitoring protects the patient and allows dose adjustments based on response.

Monthly Check-Ins

Most clinics schedule monthly telemedicine or in-person check-ins during the titration phase. These visits assess tolerability, document weight change, and screen for new symptoms such as persistent abdominal pain (which may indicate pancreatitis) or vision changes (which may indicate accelerated diabetic retinopathy in susceptible patients).

Quarterly Lab Work

After the first three months, HbA1c and a fasting metabolic panel are repeated. Patients who develop hypoglycemia symptoms need their protocol adjusted. Heart rate is also monitored: semaglutide raises mean resting heart rate by approximately 2 to 3 beats per minute, a finding documented in the SUSTAIN cardiovascular outcomes trials [7].

Annual Thyroid Screen

Because GLP-1 receptor agonists caused thyroid C-cell tumors in rodent studies, the FDA label carries a boxed warning about MTC risk. The clinical significance in humans remains uncertain, but annual TSH and calcitonin monitoring is standard practice in private clinics with a conservative risk posture [3].

The Psychology of a Private Clinic Patient

A high-profile patient accessing GLP-1 therapy through a private clinic faces barriers that are different from those of an average patient. Discretion, scheduling flexibility, and travel-compatible delivery all matter.

Discretion Protocols

Private weight-management clinics in London (where Adele is primarily based) and in Los Angeles commonly offer concierge delivery of pre-filled injection pens. Patients receive training on self-injection technique during the intake appointment. For a touring artist, this means medication can be shipped to hotel addresses or managed through a personal physician on the road.

Psychological Support Integration

The 2023 American Gastroenterological Association (AGA) Clinical Practice Guideline on pharmacological interventions for obesity notes that behavioral therapy combined with pharmacotherapy produces better outcomes than either alone [8]. Private clinics serving high-net-worth patients routinely integrate a therapist or health coach into the program at additional cost. The behavioral component addresses food-relationship patterns that resurface after GLP-1 therapy is tapered or discontinued.

The Stopping Problem

One underreported aspect of GLP-1 therapy is what happens when the drug stops. The STEP-4 trial (N=803) showed that patients who discontinued semaglutide after 20 weeks regained two-thirds of their lost weight within one year [9]. A private clinic managing a long-term patient plans for this from the outset, either by scheduling a maintenance-dose taper, incorporating a structured diet transition, or discussing the option of indefinite low-dose maintenance therapy.

Comparing the Most Plausible Protocols Side by Side

Three protocols are clinically plausible for Adele's timeline. They differ in drug, dose ceiling, and monitoring intensity.

| Protocol | Drug | Peak Dose | Expected Loss at 12 Months | Monitoring Level | |----------|------|-----------|---------------------------|-----------------| | A (Conservative) | Liraglutide 3.0 mg | 3.0 mg daily | 5 to 8% body weight | Monthly visit | | B (Standard) | Semaglutide 1.0 mg off-label | 1.0 mg weekly | 8 to 10% body weight | Quarterly lab | | C (Full STEP-1 equivalent) | Semaglutide 2.4 mg | 2.4 mg weekly | 12 to 15% body weight | Monthly visit, quarterly lab |

A loss of approximately 45 kg from a starting weight estimated at 100 kg or above is consistent with Protocol C extended over 18 to 24 months, potentially with a diet-assisted acceleration phase in the first eight weeks. Protocol B alone would not account for the full magnitude of reported change.

What the Evidence Says About Combined Diet and GLP-1 Therapy

Diet and GLP-1 combination data are not confined to case reports. The STEP-3 trial (N=611) tested semaglutide 2.4 mg alongside an intensive behavioral therapy program that included a low-calorie diet of 1,000 to 1,200 kcal per day for the first eight weeks. Mean weight loss at 68 weeks was 16.0% versus 5.7% for placebo with the same behavioral program (P<0.001) [10]. This is the closest trial analog to a combined sirtfood-style caloric restriction plus semaglutide approach.

The STEP-3 data make one point clearly: the drug does most of the work. An intensive behavioral program alone produced 5.7% loss. Adding semaglutide nearly tripled that outcome. A private-clinic patient who was already committed to a structured diet would have seen substantially amplified results with concurrent GLP-1 therapy.

Cardiovascular and Long-Term Safety Considerations

Any article that frames GLP-1 use positively must address safety. The SELECT trial (N=17,604), published in the New England Journal of Medicine in 2023, showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease, compared to placebo [11]. That finding extended the safety and benefit profile of semaglutide beyond glycemic control.

The most serious GLP-1 safety signals remain:

• Acute pancreatitis (rare, estimated at 0.1% incidence in STEP trials) [5]
• Gallbladder disease, including cholelithiasis (1.6% vs. 0.7% placebo in STEP-1) [5]
• Injection-site reactions (mild, transient in most patients)
• The theoretical MTC signal (boxed warning; no confirmed human cases to date) [3]

A private physician prescribing for a non-diabetic patient should discuss each of these with documented informed consent before initiation.

What a Responsible Private Clinic Charges and What That Buys

UK private clinics offering semaglutide-based weight programs typically charge between £150 and £350 per month for the medication, plus £100 to £200 per consultation. A full 68-week program consistent with the STEP-1 duration would cost approximately £8,000 to £18,000 all-in. US concierge programs run USD $1,200 to $2,500 per month when drug, labs, and physician time are bundled.

That price point is inaccessible to most patients, which is the central equity problem with private-clinic GLP-1 access. NHS England began funding semaglutide 2.4 mg through specialist weight-management services in March 2023, with a planned rollout through primary care. The criteria require a BMI of 35 or above and at least one comorbidity [12].

Practical Takeaways for Patients Considering a Similar Pathway

The clinical picture that emerges from analyzing the timing, reported behaviors, and available drug options is coherent. A patient in Adele's position in 2020 to 2021 who sought private weight-management care in the UK or US would have found a GLP-1 receptor agonist as the most evidence-supported pharmacological option available.

What to Ask a Private Clinic Before Starting

Any private clinic worth its fee should answer the following before prescribing:

1. What baseline labs do you require, and will you test calcitonin?
2. What is your titration schedule, and how do you handle dose reductions for side effects?
3. What happens if I need to pause for travel or illness?
4. Do you provide behavioral or nutritional support as part of the program?
5. What is your plan for discontinuation or long-term maintenance?

Red Flags That Indicate a Poor-Quality Provider

A clinic that prescribes without baseline labs, offers GLP-1 therapy to patients with BMI <27 without documented comorbidities, or fails to document informed consent for the boxed-warning risks does not meet the standard of care outlined in the Endocrine Society guidelines [6].